ACAD

ACADIA PHARMACEUTICALS INC

NasdaqHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$69.3k1 sale
Net open-market−$69.3kBuying minus selling
Active insiders1Distinct reporting owners

ACAD transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Schneyer Mark C.
Executive Vice President · Chief Financial Officer
EVP, CFO
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$69.3kView disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Oct 30, 2026

Open-market transaction mix · 1 transactions in the selected period
0 buys0%·100%1 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026010$0$69,342.48−$69,342.48
Nov 2026000$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (1)
Oct 2026: 1 insidersNov 2026: 0 insiders
Oct 2026Nov 2026
1distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
1 insider
  • SC
    Schneyer Mark C.EVP, CFO · 0 buys · 1 sale · 0 awards (A)
    −$69.3klast Oct 30
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 1 transaction on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale$69.3k
10b5-1 detected1
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
1transactionstxns
  • S · Open-market sells · dominant1 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
Chief financial officer1
EVP1

Reported Holdings After

Separated by insider, security, and ownership type

Schneyer Mark C.Common Stock · Direct
71.3k71.3kOct 30, 2026Oct 30, 2026
71,322Oct 30, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

ACADIA PHARMACEUTICALS INC Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at ACADIA PHARMACEUTICALS INC?

Schneyer Mark C..

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

Schneyer Mark C. reported a sale on Oct 30, 2026 valued at $69.3k. Read the SEC filing.

What is the recent purchase and sale balance?

Net open-market selling in the selected period was $69,342.48. Sales can occur for many non-investment reasons.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.